Kinaset Therapeutics
Boston
About Kinaset Therapeutics
Kinaset Therapeutics is a biotechnology company that develops precision medicines targeting kinase-driven diseases through selective inhibition strategies aimed at improving therapeutic profiles and addressing unmet clinical needs. Its pipeline focuses on small molecule inhibitors designed to modulate specific signalling pathways implicated in inflammatory, immune-mediated, and proliferative disorders by targeting distinct kinase enzymes with tailored selectivity. The company combines medicinal chemistry, structure-based design, and translational research to optimize compounds for efficacy, safety, and pharmacokinetic properties that support clinical evaluation. Kinaset Therapeutics collaborates with research institutions and industry partners to advance its programs and validate mechanisms of action in relevant disease models. Its development efforts prioritize therapeutic candidates that may offer differentiated treatment options for conditions driven by dysregulated kinase activity.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $144.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2026)
- Website: kinasettherapeutics.com
- Phone: +1-508-858-5810
Industries & Categories
Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/kinaset-therapeutics-24850 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.